Compare KVHI & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVHI | VERU |
|---|---|---|
| Founded | 1978 | 1971 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.7M | 36.8M |
| IPO Year | 1996 | 1996 |
| Metric | KVHI | VERU |
|---|---|---|
| Price | $7.85 | $2.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | ★ 88.5K | 50.3K |
| Earning Date | 03-10-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $9,622,000.00 | ★ $16,296,958.00 |
| Revenue This Year | $15.27 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.82 | N/A |
| 52 Week Low | $4.80 | $0.36 |
| 52 Week High | $8.48 | $4.59 |
| Indicator | KVHI | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 65.44 | 35.44 |
| Support Level | $5.30 | $2.15 |
| Resistance Level | N/A | $2.70 |
| Average True Range (ATR) | 0.53 | 0.12 |
| MACD | 0.19 | -0.03 |
| Stochastic Oscillator | 76.23 | 0.99 |
KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.